Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
=== Fusimotor system === Muscle spindles relay information to the CNS via afferents, and they receive efferent signals from the spinal cord via gamma fusimotor neurons. This gamma innervation modulates the sensitivity of muscle spindle afferents to stretch. Gamma motoneurons are categorized according to the static and dynamic response properties of the muscle spindle afferents they affect. In recordings with semi-microelectrodes inserted into peripheral nerves in humans, muscle spindle afferent firing rates increased during muscle contraction. This suggested that gamma motoneuronal activity was linked to alpha motoneuronal activity (alpha-gamma co-activation). Only small movements were studied because electrodes otherwise dislodged. In studies of locomotion in decerebrate cats, gamma activity was shown to be correlated with cyclical variations in joint angle. In cats performing normal walking, beam-walking, landing from falls and resisting imposed movement, the mean firing rates of muscle spindle primary afferents and their sensitivity to variations in muscle length changed according to task. Sensitivity greatly increased in difficult tasks and in states of vigilance, presumably due to increases in dynamic gamma activity. The terms fusimotor "wind-up" and fusimotor "set" were coined to describe these behaviors.
Negrin opened wide, fascinating vistas to my imagination, not only through his lectures and laboratory teaching, but through his advice, encouragement, and stimulation to read scientific monographs and textbooks in languages other than Spanish. Negrín encouraged Ochoa and another student, José Valdecasas, to isolate creatinine from urine. The two students succeeded and also developed a method to measure small levels of muscle creatinine. Ochoa spent the summer of 1927 at University of Glasgow working with D. Noel Paton on creatine metabolism and improving his English skills. He also refined the assay procedure further and upon returning to Spain he and Valdecasas submitted a paper describing the work to the Journal of Biological Chemistry, where it was rapidly accepted, marking the beginning of Ochoa's biochemistry career. Ochoa completed his undergraduate medical degree in the summer of 1929 and decide to go abroad again to gain further research experience. His creatine and creatinine work led to an invitation to join Otto Meyerhof's laboratory at the Kaiser Wilhelm Institute for Biology in Berlin-Dahlem in 1929. At that time the institute was a "hot bed" of the rapidly evolving discipline of biochemistry, and thus Ochoa had the experience of meeting and interacting with scientists such as Otto Heinrich Warburg, Carl Neuberg, Einar Lundsgaard, and Fritz Lipmann in addition to Meyerhof who had received the Nobel Prize in Physiology and Medicine less than a decade earlier.
==== Government ==== Iran delivered its response to the United States via Pakistan rejecting a temporary ceasefire and listed their own 10-point proposal, which includes a solution to all regional conflicts, lifting of sanctions, reconstruction, and a protocol to re-open the Strait of Hormuz. Iranian Ambassador to Pakistan, Reza Amiri-Moghaddam said on X (formerly Twitter) that the talks reached a "critical, sensitive stage". Iranian parliamentary speaker Mohammad Bagher Ghalibaf said that the agreement had been violated, and argued that "a bilateral ceasefire or negotiations is unreasonable." On 9 April, he said that "time is running out" for the ceasefire to be viable. Following the implementation of the ceasefire, a written statement in the name of Mojtaba Khamenei was read on state-run television saying saying to stop firing for the time being, with another message promising revenge. Mohammad Eslami said that any attempt to limit Iran's enrichment of uranium would fail. According to Pakistani sources Iran was about to retaliate on the night between 8 and 9 April against Israeli violations of the ceasefire in Lebanon, however, Pakistani diplomatic efforts managed to hold back such response. Hamid-Reza Haji Babaee, Deputy Speaker of the Iranian Parliament, said that he has faith in the military but not in the negotiations.
Increased oxygen consumption during sustained exercise reduces the oxygen saturation of venous blood, which can reach less than 15% in a trained athlete; although breathing rate and blood flow increase to compensate, oxygen saturation in arterial blood can drop to 95% or less under these conditions. Oxygen saturation this low is considered dangerous in an individual at rest (for instance, during surgery under anesthesia). Sustained hypoxia (oxygenation less than 90%), is dangerous to health, and severe hypoxia (saturations less than 30%) may be rapidly fatal. A fetus, receiving oxygen via the placenta, is exposed to much lower oxygen pressures (about 21% of the level found in an adult's lungs), so fetuses produce another form of hemoglobin with a much higher affinity for oxygen (hemoglobin F) to function under these conditions.
McLeod syndrome ( mə-KLOWD) is an X-linked recessive genetic disorder that may affect the blood, brain, peripheral nerves, muscle, and heart. It is caused by a variety of recessively inherited mutations in the XK gene on the X chromosome. The gene is responsible for producing the Kx protein, a secondary supportive protein for the Kell antigen on the red blood cell surface.
Sources: en.wikipedia.org
=== Dyeing === The use of Prussian blue and other dyes (often in conjunction with bonding treatments) to "enhance" its appearance, make uniform or completely change the colour, is regarded as fraudulent by some purists, especially since some dyes may fade or rub off on the wearer. Dyes have also been used to darken the veins of turquoise.
== Metal catalysts == Metals such as iron, copper, chromium, vanadium, and cobalt are capable of redox cycling in which a single electron may be accepted or donated by the metal. This action catalyzes production of reactive radicals and reactive oxygen species. The presence of such metals in biological systems in an uncomplexed form (not in a protein or other protective metal complex) can significantly increase the level of oxidative stress. These metals are thought to induce Fenton reactions and the Haber-Weiss reaction, in which hydroxyl radical is generated from hydrogen peroxide. The hydroxyl radical then can modify amino acids. For example, meta-tyrosine and ortho-tyrosine form by hydroxylation of phenylalanine. Other reactions include lipid peroxidation and oxidation of nucleobases. Metal-catalyzed oxidations also lead to irreversible modification of arginine, lysine, proline, and threonine. Excessive oxidative-damage leads to protein degradation or aggregation. The reaction of transition metals with proteins oxidized by reactive oxygen or nitrogen species can yield reactive products that accumulate and contribute to aging and disease. For example, in Alzheimer's patients, peroxidized lipids and proteins accumulate in lysosomes of the brain cells.
=== European Union === In the European Union, semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes. Semaglutide (as Wegovy) is further indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with obesity (initial BMI ≥ 30 kg/m2) or who are overweight (initial BMI ≥ 27 kg/m2) and have at least one weight-related comorbidity such as dysglycemia (prediabetes or type 2 diabetes), hypertension, dyslipidemia, or cardiovascular disease. It is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents (aged twelve years and older) with obesity and body weight above 60 kg (130 lb). Semaglutide (as Kayshild) is indicated in conjunction with diet and exercise for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced liver fibrosis (stage F2 or F3).
== History and research == From 2002, when the first description of a CDPSs was done, until now, the number of reported CDPSs in databases has experienced a significant growth (800 in June 2017). It is probable that these cyclopeptides are implicated in numerous biosynthetic pathways. However, their products’ diversity has not been very explored. The activity of 32 new CPDS has been described. This fact raises the number of experimentally characterized CDPS up to 100 (approximately). Moreover, this research has identified several consensus sequences associated to the formation of a specific cyclodipeptide, enhancing the predictive model of specificity of CDPS. This improved prediction method facilitates the deciphering of independent ways of CDPS.
=== DAP pathway === The DAP pathway is found in both prokaryotes and plants and begins with the dihydrodipicolinate synthase (DHDPS) (E.C 4.3.3.7) catalysed condensation reaction between the aspartate derived, L-aspartate semialdehyde, and pyruvate to form (4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinic acid (HTPA). The product is then reduced by dihydrodipicolinate reductase (DHDPR) (E.C 1.3.1.26), with NAD(P)H as a proton donor, to yield 2,3,4,5-tetrahydrodipicolinate (THDP). From this point on, four pathway variations have been found, namely the acetylase, aminotransferase, dehydrogenase, and succinylase pathways. Both the acetylase and succinylase variant pathways use four enzyme catalysed steps, the aminotransferase pathway uses two enzymes, and the dehydrogenase pathway uses a single enzyme. These four variant pathways converge at the formation of the penultimate product, meso‑diaminopimelate, which is subsequently enzymatically decarboxylated in an irreversible reaction catalysed by diaminopimelate decarboxylase (DAPDC) (E.C 4.1.1.20) to produce L-lysine. The DAP pathway is regulated at multiple levels, including upstream at the enzymes involved in aspartate processing as well as at the initial DHDPS catalysed condensation step. Lysine imparts a strong negative feedback loop on these enzymes and, subsequently, regulates the entire pathway.
Sources: en.wikipedia.org
=== Veterinary use === An SSRI (fluoxetine) has been approved for veterinary use in treatment of canine separation anxiety. Like in human medicine, fluoxetine is extensively used off-label in animal medicine. In dogs and cats, it is mainly prescribed off-label for behavior problems.
== History == The sequence of human GM-CSF was first identified in 1985 and soon three recominbant human GM-CSFs were produced, one in bacteria, one in mammalian cells, and one in yeast; Immunex developed GM-CSF manufactured in yeast into Leukine. Clinical trials of sargramostim were initiated in 1987; in that same year it was administered to six people as part of a compassionate-use protocol for the victims of cesium irradiation from the Goiânia accident. It was approved by the FDA in March 1991, under the brand name Leukine for acceleration of white blood cell recovery following autologous bone marrow transplantation in people with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease. In November 1996, the FDA also approved sargramostim for treatment of fungal infections and replenishment of white blood cells following chemotherapy. A liquid formulation was approved in 1995. Immunex was acquired by Amgen in 2002. As part of the acquisition, Leukine was spun off to Berlex, which became Bayer HealthCare in 2007. In January 2008, Bayer informed healthcare professionals of the market withdrawal of the current liquid formulation of sargramostim. The liquid formulation was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change that was made to the formulation around April 2007 to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates had not been observed with the use of lyophilized sargramostim.
== Comparison with open-weights AI == The Open Source Initiative distinguishes open-source from open weights artificial intelligence when the materials needed to study and modify the model's development process are not also available.
Endre Mester (1903–1984) was a Hungarian physician and pioneer of laser medicine, especially the use of low level laser therapy (LLLT). In 1967, only a few years after the first working laser was invented, he started his experiments with the effects of lasers on skin cancer. He is credited as the discoverer of positive biological effects of low power lasers, which have been advocated as alternative medicine for use in wound healing, smoking cessation, tuberculosis, temporomandibular joint disorders, and musculoskeletal conditions such as carpal tunnel syndrome, fibromyalgia, osteoarthritis, and rheumatoid arthritis. LLLT devices are popular and may bring about temporary relief of some types of pain. As of 2009, a summary from Quackwatch reported medical authorities found no reason to believe LLLT influence the course of any ailment or are more effective for pain control than other forms of heat delivery. Subsequent research has found LLLT may offer benefit in treating several health ailments, including rheumatoid arthritis, osteoarthritis, tendinopathy, and frozen shoulders.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.